Sugi Holdings Co.,Ltd. Revises Earnings Guidance for the Fiscal Year Ended February 29, 2024
March 26, 2024 at 02:30 am EDT
Share
Sugi Holdings Co.,Ltd. revised earnings guidance for the fiscal year ended February 29, 2024. For the year, the company expects net sales of JPY 742,500 million, operating profit of JPY 36,500 million, profit attributable to owners of parent of JPY 21,500 million and earnings per share of JPY 356.44 compared to previous guidance of net sales of JPY 742,500 million, operating profit of JPY 35,000 million, profit attributable to owners of parent of JPY 20,500 million and earnings per share of JPY 339.87. Reasons for the revision: In the third quarter results (December 26, 2023), the Company upwardly revised its full-year forecast, mainly due to an
increase in demand for cosmetics as a result of the easing of behavioral restrictions and a gradual recovery in inbound
demand, and sales continue to be strong and profitability has further improved. Since operating income, ordinary income, and net income attributable to owners of the parent are all expected to exceed the previously announced forecasts, the full-year consolidated forecasts have been revised upward again.
SUGI HOLDINGS CO.,LTD. is a Japan-based holding company mainly engaged in management of the drug stores and dispensing business. Through its subsidiaries, the Company is engaged in the sale of medicines, health foods, cosmetics, daily necessities and prescription preparations, as well as the operation of local healthcare compliant drug store that tackles home healthcare in cooperation with regional medical personnel. The Company also operates visiting nursing stations that closely cooperate with regional medical institutions and social welfare operators, through the provision of visiting nursing services and in-home nursing care support services.